Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host cells via an interaction between its Spike protein and the host cell receptor angiotensin-converting enzyme 2 (ACE2). By screening a yeast surface-displayed library of synthetic nanobody sequences, we developed nanobodies that disrupt the interaction between Spike and ACE2. Cryo-electron microscopy (cryo-EM) revealed that one nanobody, Nb6, binds Spike in a fully inactive conformation with its receptor binding domains locked into their inaccessible down state, incapable of binding ACE2. Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for Spike and picomolar neutralization of SARS-CoV-2 infection. mNb6-tri retains function after aerosolization, lyophilization, and heat treatment, which enables aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857409 | PMC |
| http://dx.doi.org/10.1126/science.abe3255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A synthetic humanized camelid single-domain antibody targeting VEGF exhibits in vitro antiangiogenic effects.
Int Immunopharmacol
September 2025
Center for Genetic Engineering and Biotechnology, Cubanacan, 10600 Havana, POBox 6162, Cuba. Electronic address:
Vascular endothelial growth factor (VEGF) is a key player in the development and progression of several diseases, most notably cancer and retinal disorders. Over the last twenty years, VEGF has emerged as a significant therapeutic target for these conditions. This study reports the isolation and characterization of a fully synthetic, humanized, affinity-matured single-domain antibody fragment (VHH) designed to target VEGF.
View Article and Find Full Text PDFPhagocytic clearance of targeted cells with a synthetic ligand.
Nat Biomed Eng
September 2025
Institute for Integrated Cell-Material Sciences, Kyoto University, Yoshida-Honmachi, Sakyoku, Kyoto, Japan.
During the process of engulfment, phosphatidylserine is exposed on the surface of dead cells as an 'eat-me' signal and is recognized by Protein S (ProS), a secreted factor that also binds to the Mer tyrosine kinase (MerTK) on phagocytes. Despite its robust activity, this engulfment mechanism has not been exploited for therapeutic purposes. Here we develop a synthetic protein modality called Crunch (connector for removal of unwanted cell habitat) by modifying ProS, inspired by the high engulfment capability of the ProS-MerTK pathway.
View Article and Find Full Text PDFNanoengineering of Exosomal Surfaces for Precision Targeting and Payload Delivery at the Molecular Level.
Assay Drug Dev Technol
September 2025
School of Applied Sciences, CT University, Sidhwan Khurd, India.
Resurfacing promotes antibacterial activity of a lipid A-binding nanobody.
Proc Natl Acad Sci U S A
September 2025
Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.
Nanobodies have been pursued as candidates for antimicrobial design due to their small size and versatile binding capacities, but direct antibacterial activity of a nanobody has yet to be described. Here, we employed a bacterial surface display platform to screen a synthetic library of nanobody variants for antimicrobial potential. We identified a candidate that binds the essential lipid A component of gram-negative lipopolysaccharide.
View Article and Find Full Text PDFFrom immune evasion to broad binding: computational optimization of SARS-CoV-2 RBD-targeting nanobody.
Front Immunol
September 2025
Department of Physics, School of Science, Tianjin University, Tianjin, China.
Introduction: The rapid evolution of SARS-CoV-2 Omicron variants highlights the urgent need for therapeutic strategies that can target viral evolution and leverage host immune recognition mechanisms. This study uses molecular dynamics (MD) simulations to analyze the immune evasion mechanisms of class 1 nanobodies against emerging SARS-CoV-2 variants, and to develop an efficient pipeline for rapid affinity optimization.
Methods: We employed MD simulations and binding free energy calculations to investigate the immune evasion mechanisms of four class 1 nanobodies (R14, DL4, V ab6, and Nanosota9) against wild-type (WT) and Omicron variants, including BA.